Business Context and Reporting Period
This Form 8-K Current Report for Alzamend Neuro, Inc. (ALZN) covers events occurring on January 31, 2024, and February 1, 2024, with a report date of February 2, 2024. The Company is an emerging growth company incorporated in Delaware and listed on the Nasdaq Capital Market. The filing primarily addresses a new financing agreement and a regulatory notice regarding stock listing compliance.
Key Financial Metrics and Capital Structure
The filing details a specific financing transaction rather than providing comprehensive period-over-period financial statements (e.g., revenue, net income, or operating cash flow).
- Financing Agreement: Entered into a Securities Purchase Agreement with Ault Lending, LLC (an affiliate) to sell up to $6 million of Series A Convertible Preferred Stock and associated warrants.
- Initial Closing: Sold 1,220 shares of Series A Convertible Preferred Stock and warrants to purchase 1,220,000 shares of Common Stock for a total purchase price of $1.22 million.
- Payment Method: The $1.22 million purchase price was paid via the cancellation of existing cash advances made by the Purchaser to the Company between November 9, 2023, and January 31, 2024.
- Debt/Liquidity Impact: The transaction converted $1.22 million of cash advances into equity instruments (Preferred Stock and Warrants).
- Stock Price Status: The Common Stock bid price closed below $1.00 per share for 30 consecutive business days prior to February 1, 2024.
Material Changes and Transaction Terms
The filing outlines significant changes to the Company's capital structure and listing status:
- Series A Convertible Preferred Stock:
- Stated Value: $1,000 per share.
- Conversion Price: $1.00 per share (subject to anti-dilution adjustments).
- Liquidation Preference: Holders receive the Stated Value before Common Stock holders in a liquidation or change of control.
- Voting Rights: Vote on an as-converted basis, subject to a "Voting Floor Price" of $0.873 to comply with Nasdaq regulations.
- Warrants:
- Exercise Price: $1.20 per share (subject to adjustments).
- Term: Five-year term, exercisable starting six months after issuance.
- Quantity: Equal to the number of Conversion Shares issuable upon the Preferred Stock issued at each closing.
- Financing Timeline:
- Up to $2 million available for purchase by March 31, 2024.
- Up to $4 million available for purchase between April 1, 2024, and March 31, 2025 (Termination Date).
- Nasdaq Delisting Notice: Received a Deficiency Letter on February 1, 2024, for failing to maintain a minimum bid price of $1.00. The Company has 180 days (until July 30, 2024) to regain compliance.
Outlook, Risks, and Management Commentary
- Compliance Risk: There is no assurance the Company will regain compliance with the Nasdaq Minimum Bid Price requirement by July 30, 2024. Failure to do so could result in delisting.
- Remediation Options: The Company may evaluate options to resolve the deficiency, including a reverse stock split, if eligible for a second compliance period.
- Shareholder Approval: Issuance of shares is capped at 19.99% of outstanding Common Stock without shareholder approval. The Company agreed to file a proxy statement to obtain this approval.
- Unregistered Sales: The securities were sold in reliance on Section 4(a)(2) of the Securities Act of 1933.
Investor Verification Checklist
- Verify the Company's ability to maintain the $1.00 minimum bid price for 10 consecutive days before July 30, 2024, to avoid delisting.
- Confirm the status of the proxy statement filing required to obtain shareholder approval for issuances exceeding the 19.99% threshold.
- Monitor the utilization of the remaining $4.78 million financing capacity under the agreement with Ault Lending, LLC.
- Review the impact of the $1.22 million debt-to-equity conversion on the Company's current liquidity position.
- Check for any subsequent filings regarding the outcome of the Nasdaq compliance period or potential reverse stock split proposals.